{
  "docId": "019dd923-622c-750b-8b9a-4b91788fc785",
  "docSlug": "5fadb686cc03",
  "documentTitle": "Twist Bioscience (TWST)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2022-11-15 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2941177,
  "pageNumber": 183,
  "pageCount": 236,
  "prevPage": 182,
  "nextPage": 184,
  "slideType": "section_divider",
  "function": "transition",
  "density": "sparse",
  "nDataPoints": 0,
  "notes": "The slide acts as a narrative transition, framing the upcoming section as a critique of the company's growth sustainability.",
  "elementsJson": [
    "paragraph"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-4b91788fc785/183",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-4b91788fc785#slide-183",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Twist exhibits telling signs that its “growth” is about to hit the wall and that the end is near, beyond the accounting games that typically signal desperation: saturation in its tiny niche; competitive struggles; and an impending flood of disruptive, venture-backed entrants with newer DNA synthesis technologies, which even Twist’s customers describe as an existential threat.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-0932-77cf-bff2-ece43ed41e06",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Part VI: Twist exhibits telling signs that its “growth” is about to hit the wall and that the end is near, beyond the accounting games that typically signal desperation: saturation in its tiny niche; competitive struggles; and an impending flood of disruptive, venture-backed entrants with newer DNA synthesis technologies, which even Twist’s customers describe as an existential threat.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "da46c72a-559e-456a-b6ef-09410572dd15",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}